Author Question: A patient is diagnosed with peptic ulcer disease complicated by H. pylori. What is the rationale for ... (Read 72 times)

aabwk4 · **on:** Jul 23, 2018

A patient is diagnosed with peptic ulcer disease complicated by H. pylori. What is the rationale for adding bismuth to the patient's medication regimen?

A) Increases pepsin activity
B) Decreases gastrin secretion
C) Prevents metabolic alkalosis
D) Protects gastric mucosa from stomach acid

Question 2

A patient's current drug regimen includes intranasal administration of desmopressin acetate (DDAVP, Stimate). In this patient's plan of nursing care, what is the most likely desired outcome of treatment?

A) The patient's urine output will not exceed 80 mL/h.
B) The patient will gain 2 cm in height over the next 6 months.
C) The patient will ovulate at least once over the next 8 weeks.
D) The patient's vertical growth will cease in the next 4 weeks.

coreycathey · **Reply #1 on:** Jul 23, 2018

Answer to Question 1

D
Feedback:
Health care providers use bismuth subsalicylate to coat ulcers, protecting them from stomach acid to treat H. pylori. Bismuth does not increase pepsin activity, decrease gastrin secretion, or prevent metabolic alkalosis.

Answer to Question 2

A
Feedback:
Desmopressin acetate (DDAVP, Stimate) is the prototype posterior pituitary hormone medication. It is used to treat diabetes insipidus. Consequently, reduced urine output is the primary goal of treatment. The drug does not influence growth or ovulation.